These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1909485)

  • 81. Transdermal lisuride delivery in the treatment of Parkinson's disease.
    Woitalla D; Müller T; Benz S; Horowski R; Przuntek H
    J Neural Transm Suppl; 2004; (68):89-95. PubMed ID: 15354393
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease.
    Capria A; Attanasio A; Quatrana M; Cannata D; Fioravanti M; Stocchi F; Ruggieri S
    Clin Neuropharmacol; 1989 Aug; 12(4):331-8. PubMed ID: 2804995
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Optoelectronic movement analysis in Parkinson's disease: effect of selegiline on the disability in de novo parkinsonian patients--a pilot study.
    Johnels B; Ingvarsson PE; Matousek M; Steg G; Heinonen EH
    Acta Neurol Scand Suppl; 1991; 136():40-3. PubMed ID: 1801536
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Orally disintegrating selegiline for the treatment of Parkinson's disease.
    Löhle M; Storch A
    Expert Opin Pharmacother; 2008 Nov; 9(16):2881-91. PubMed ID: 18937619
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Treatment of Parkinson's disease with NADH.
    Dizdar N; Kågedal B; Lindvall B
    Acta Neurol Scand; 1994 Nov; 90(5):345-7. PubMed ID: 7887134
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain.
    Micieli G; Martignoni E; Bono G; Cavallini A; Rossi F; Horowski R; Nappi G
    Clin Neuropharmacol; 1989 Oct; 12(5):404-15. PubMed ID: 2692810
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.
    Oakley F; Sunderland T
    Int Psychogeriatr; 1997 Jun; 9(2):197-206. PubMed ID: 9309491
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pharmacokinetics of lisuride after subcutaneous infusion.
    Krause W; Nieuweboer B; Ruggieri S; Stocchi F; Suchy I
    J Neural Transm Suppl; 1988; 27():71-4. PubMed ID: 3165439
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Terguride in parkinsonism. A multicenter trial.
    Filipová M; Filip V; Macek Z; Müllerová S; Marková J; Kás S; Zizková B; Krivka J; Votavová M; Krejcová H
    Eur Arch Psychiatry Neurol Sci; 1988; 237(5):298-303. PubMed ID: 3049101
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Monitoring the Level of
    Kalász H; Tekes K; Faigl EB; Pöstényi Z; Berekméri E; Karvaly G; Adeghate E
    Open Med Chem J; 2017; 11():1-8. PubMed ID: 28567124
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Lisuride toxicity in a pediatric patient.
    Alahmadi TA; Mujawar QM
    J Emerg Trauma Shock; 2013 Apr; 6(2):140-2. PubMed ID: 23723628
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Patient with Parkinson's disease presenting with impulse control disorders following treatment with selegiline.
    Hirao K; Kaneko Y; Hirose D; Fukasawa R; Shimizu S; Kanetaka H; Umahara T; Sakurai H; Hanyu H
    Int Psychogeriatr; 2019 Sep; 31(9):1375-1376. PubMed ID: 30520410
    [No Abstract]   [Full Text] [Related]  

  • 98. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.
    Wang K; Liu ZH; Li XY; Li YF; Li JR; Hui JJ; Li JX; Zhou JW; Yi ZM
    Front Aging Neurosci; 2023; 15():1134472. PubMed ID: 37113570
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
    Tan YY; Jenner P; Chen SD
    J Parkinsons Dis; 2022; 12(2):477-493. PubMed ID: 34957948
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
    Riederer P; Müller T
    J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.